CHEERS Checklist

Items to include when reporting economic evaluations of health interventions

The **ISPOR CHEERS Task Force Report**, Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluations Publication Guidelines Good Reporting Practices Task Force, provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the Value in Health or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp

Section/item	ltem No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract				
Title	1	Identify the study as an economic evaluation or use more specific terms such as "cost-effectiveness analysis", and describe the interventions compared.	Page 1, Line 3-4	Title
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	Page 2, Line 25-47	Abstract, Paragraph 1-4
Introduction				
Background and objectives	3	Provide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or practice decisions.	Page 3-4, Line 56-98	Introduction, Paragraph 1-4
Methods	1			
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	Page 4, Line 106-110	Methods, Paragraph 1
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	Page 4, Line 95-98	Introduction, Paragraph 4
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	Page 5, Line 120-121	Methods, Paragraph 2
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	Page 4, Line 110-114	Methods, Paragraph 1
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	Page 4, Line 116-118	Methods, Paragraph 2
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	Page 5, Line 119-120	Methods, Paragraph 2
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	Page 5, Line 149	Utility estimates, Paragraph 1

effectiveness int study was a sufficient source of clinical effectiveness data. Pangraph I 11b synthesis-based estimates: Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data. NA Single study estimates Measurement and valuation of preference based if applicable, describe the population and methods used to elicit preferences for outcomes. Pangraph I Single study-based economic evaluation: Describe approaches used to estimate resource use associated with the resource use associated with the sun in cost. Describe any adjustments made to approximate to opportunity costs. NA Model-based economic evaluation: Describe primary or secondary research methods for valuing each resource use associated with the its unit cost. Describe any adjustments made to approximate to opportunity costs. NA Model-based economic evaluation: Describe primary or secondary research methods for valuing each resource use associated with the its unit cost. Describe any adjustments made to approximate to opportunity costs. NA Model-based economic evaluation: Describe approaches and data sources used to estimate resource use associated with the its unit cost. Describe any adjustments made to approximate to opportunity costs. Na Model-based economic evaluation: Describe primary or secondary research methods for converting costs into a common currency base and the exchange rate. Na Model-based economic evaluation: Describe primary or secondary research methods for converting costs into a common currency base and the exchange rate. Na Na Model-based ec					
clinical effectiveness data.cellinical effectiveness data.cellinitasMeasurement and valuation of preference based outcomes12If applicable, describe the population and methods used to elicit preferences for outcomes.Page 6, Line 152-153Willing esti- paragraph 1Estimating resources and costs13aSingle study-based economic evaluation: Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.NAModel base evaluationCurrency, price date, and costs to the year of reported costs if necessary. Describe methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.Page 6, Line 137-142.W Page 6, Line 137-142.W Page 6, Line 137-141.W Page 6, Line 137-141 Page 6, Line 137-141Model base evaluationCurrency, price date, and conversion13bModel-base deconomic evaluation: Describe approaches and data sources used to estimate resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.Page 6, Line 137-142.W Page 6, Line 137-142.WModel base evaluationCurrency, price date, and costs to the year of reported costs if necessary. Describe methods for valuing estimated unit costs to the year of reported costs if necessary. Describe methods for columing a figure to show model and the exchange rate.Page 4, Line 102-1038-115-116Methods.PAssumptions16Describe and give reasons for the specific type of decision-analyti			e effectiveness study and why the single	Page 5-6, Line 149-152	Utility estimates, Paragraph 1
and valuation of preference based outcomesImage: Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-			n of included studies and synthesis of	NA	Single study-based estimates
resources and costsatternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.Page 5, Line 133-142,& Page 6, Line 153-161evaluation 	and valuation of preference based	If applicable, describe the population and methods used to elicit preference	for outcomes.	Page 6, Line 152-153	Utility estimates, Paragraph 1
with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.Page 6, Line 157-161progression progression Pragraph I 	resources and	alternative interventions. Describe primary or secondary research methods t	or valuing each resource item in terms of	NA	Model-based economic evaluation
price date, and conversioncosts to the year of reported costs if necessary. Describe methods for converting costs into a common currency baseParagraph 1Choice of model15Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended.Page 4. Line 102-103&115-116Methods, PAssumptions16Describe all structural or other assumptions underpinning the decision-analytical model.Page 4.5, Line 115-119Methods, PAnalytical methods17Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for analytical population heterogeneity and uncertainty.Page 13-14, Line 377 Page 6, Line 168-175 Page 6, Line 168-175 Page 6, Line 168-175 Page 6, Line 182-186Table 2 Safety para Safety para		with model health states. Describe primary or secondary research methods	or valuing each resource item in terms of		Model survival and progression risk estimates, Paragraph 1& Measurement of costs
Image: structure is strongly recommended.102-103&115-116Assumptions16Describe all structural or other assumptions underpinning the decision-analytical model.Page 4-5, Line 115-119Methods, Page 4-5, Line 115-119Analytical methods17Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty.Page 5, Line 130-145Model surv progression Paragraph 1ResultsStudy parameters18Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or is strongly recommended.Page 13-14, Line 357 Page 6, Line 168-175 Page 6-7, Line 182-186Table 2 Safety para 	price date, and	costs to the year of reported costs if necessary. Describe methods for conve		Page 6, Line 158-161	Measurement of costs, Paragraph 1
Analytical methods 17 Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty. Page 5, Line 130-145 Model surv progression Paragraph 1 Results Study parameters 18 Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or is strongly recommended. Page 13-14, Line 357 Page 6, Line 168-175 Page 6-7, Line 182-186 Table 2 Safety para Sensitivity	Choice of model		used. Providing a figure to show model		Methods, Paragraph 1-2
missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty. progression Paragraph 1 Results Study parameters 18 Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended. Page 13-14, Line 357 Page 6, Line 168-175 Page 6-7, Line 182-186 Table 2 Safety para Sensitivity	Assumptions	Describe all structural or other assumptions underpinning the decision-analy	tical model.	Page 4-5, Line 115-119	Methods, Paragraph 2
Study parameters 18 Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended. Page 13-14, Line 357 Page 6, Line 168-175 Page 6, Line 168-175 Page 6-7, Line 182-186 Table 2	Analytical methods	missing, or censored data; extrapolation methods; methods for pooling data adjustments (such as half cycle corrections) to a model; and methods for ha	; approaches to validate or make	Page 5, Line 130-145	Model survival and progression risk estimates, Paragraph 1
sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended.	Results				
Incremental agents 10 Ear agent intervention report mean values for the main astrogories of estimated agents and autoempa of intervent agent Deve 7. Lies 105 2011 Develop De	Study parameters	sources for distributions used to represent uncertainty where appropriate. P		Page 6, Line 168-175	Table 2 Safety parameters Sensitivity analysis
and outcomes well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios.	Incremental costs and outcomes	For each intervention, report mean values for the main categories of estimat well as mean differences between the comparator groups. If applicable, rep		Page 7, Line 195-201	Results, Base-case results

Characterising uncertainty	20a	Single study-based economic evaluation: Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact of methodological assumptions (such as discount rate, study perspective).	NA	Model-based economic evaluation
	20b	<i>Model-based economic evaluation:</i> Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.	Page 7-8, Line 204-219	Sensitivity analysis, Paragraph 1-2
Characterising heterogeneity	21	If applicable, report differences in costs, outcomes, or cost- effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.	NA	Unable to obtain variations between subgroups of patients
Discussion		·		
Study findings, limitations, generalisability, and current knowledge	22	Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge.	Page 8-9, Line 223-259	Discussion, Paragraph 1-3
Other		·		
Source of funding	23	Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	Page 9, Line 270-273	Acknowledgments
Conflicts of interest	24	Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	Page 9, Line 276	Footnote

For consistency, the CHEERS Statement checklist format is based on the format of the CONSORT statement checklist

The **ISPOR CHEERS Task Force Report** provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the *Value in Health* link or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp

The citation for the CHEERS Task Force Report is:

Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—Explanation and elaboration: A report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health 2013;16:231-50.

Article information: https://dx.doi.org/10.21037/tlcr-23-456

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.